Skip to main content
SpringerLink
Log in

Oral Chemotherapy for the Older Patient with Cancer

  • Review Article
  • Published:
American Journal of Cancer

Abstract

Oral chemotherapy presents a number of theoretical advantages in older cancer patients, including convenience of administration and dosage flexibility.

Of the oral fluorinated pyrimidines, capecitabine is the most promising, because it minimizes the exposure of normal tissue to the active drug and substantially reduces the risk of mucositis, that is particularly common and severe in the aged. Despite promising initial results, oral etoposide does not offer any special advantage over the intravenous formulation for older patients, while oral temozolomide may have a role in the palliation of malignant melanoma and primary and secondary brain tumors. Of the experimental agents, oral platinum (satraplatin) and oral taxane formulations appear to be the most promising for minimization of the toxicity of the corresponding intravenous drug. Of special interest are tumor-specific agents, including inhibitors of tyrosine phosphokinase (e.g. imatinib mesylate) and angiogenesis. In conclusion, oral chemotherapy of cancer appears to be a very promising option for older patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Table II
Table III
Fig. 1

Similar content being viewed by others

References

  1. Balducci L, Extermann M. A practical approach to the older cancer patient. Curr Probl Cancer 2001; 25(1): 6–76

    PubMed  CAS  Google Scholar 

  2. Yancik RM, Ries L. Cancer and age: magnitude of the problem. In: Balducci L, Lyman GH, Ershler WB, editors. Comprehensive geriatric oncology. London: Harwood Academic Publishers, 1998: 95–114

    Google Scholar 

  3. Balducci L, Extermann M. Cancer and aging: an evolving panorama. Hematol Oncol Clin North Am 2000; 4: 1–12

    Article  Google Scholar 

  4. Balducci L, Yates G. General guidelines for the management of the older patients with cancer. Oncology (Hunting!) 2000 Nov; 14(11A): 221–7

    CAS  Google Scholar 

  5. Balducci L, Extermann M. Cancer in the older patient: a practical approach. Oncologist 2000; 5: 224–37

    Article  PubMed  CAS  Google Scholar 

  6. Balducci L, Lyman GH. Patients aged ≥ 70 are at high risk for neutropenic infection and should receive hemopoietic growth factors when treated with moderately toxic chemotherapy. J Clin Oncol 2001 Mar 1; 19(5): 1583–5

    PubMed  CAS  Google Scholar 

  7. Vestal RE. Aging and pharmacology. Cancer 1997; 80: 1302–10

    Article  PubMed  CAS  Google Scholar 

  8. Baker SD, Grochow LB. Pharmacology of cancer chemotherapy in the older person. Clin Geriatr Med 1997; 13: 169–84

    PubMed  CAS  Google Scholar 

  9. Balducci L, Corcoran MB. Antineoplastic chemotherapy of the older cancer patient. Hematol Oncol Clin North Am 2000; 14: 193–212

    Article  PubMed  CAS  Google Scholar 

  10. Duthie E. Physiology of aging: relevance to symptom perceptions and treatment tolerance. In: Balducci L, Lyman GH, Ershler WB, editors. Comprehensive geriatric oncology. London: Harwood Academic Publishers, 1998: 247–62

    Google Scholar 

  11. Borkowski JM, Duerr M, Donehower RC, et al. Relation between age and clearance rate of nine investigational anticancer drugs from phase I pharmacokinetics data. Cancer Chemother Pharmacol 1994; 33: 493–6

    Article  PubMed  CAS  Google Scholar 

  12. Gurney H. Dose calculation of anticancer drugs: a review of the current practice and introduction of an alternative. J Clin Oncol 1996; 14: 2590–611

    PubMed  CAS  Google Scholar 

  13. Lichtman SM, Skirvin JA. Pharmacology of antineoplastic agents in older cancer patient. Oncology (Huntingt) 2000 Mar; 66(3): 224–6

    Google Scholar 

  14. Pierelli L, Perillo A, Greggi S, et al. Erythropoietin addition to granulocyte-colony stimulating factor abrogates life-threatening neutropenia and increases peripheral blood progenitor-cell mobilization after epirubicin, paclitaxel and cisplatin in combination chemotherapy. J Clin Oncol 1999; 17: 1288–96

    PubMed  CAS  Google Scholar 

  15. Ratain MJ, Schilsky RL, Choi KE, et al. Adaptive control of etoposide administration: impact of interpatient pharmacodynamic variability. Clin Pharmacol Ther 1989; 45: 226–33

    Article  PubMed  CAS  Google Scholar 

  16. Silber JH, Fridman M, Di Paola RS, et al. First-cycle blood counts and subsequent neutropenia, dose reduction or delay in early stage breast cancer therapy. J Clin Oncol 1998; 16: 2392–400

    PubMed  CAS  Google Scholar 

  17. Extermann M, Chen A, Cantor AB, et al. Predictors of toxicity from chemotherapy in older patients [abstract]. Proc Am Soc Clin Oncol 2000; 19: 617a

    Google Scholar 

  18. Schijvers D, Highley M, DeBruyn E, et al. Role of red blood cell in pharmakinetics of chemotherapeutic agents. Anticancer Drugs 1999; 10: 147–53

    Article  Google Scholar 

  19. Balducci L, Hardy CL. Anemia of aging: a model of erythropoiesis in cancer-patients. Cancer Control 1998; 5(2 Suppl. 1): 17–21

    PubMed  Google Scholar 

  20. Balducci L, Ershler WB. Anemia and aging. Arch Int Med. In press

  21. Lancet JE, Willman CL, Bennett JM. Acute myelogenous leukemia and aging: clinical interactions. Hematol Oncol Clin North Am 2000; 16: 251–68

    Article  Google Scholar 

  22. Jacobson SD, Cha S, Sargent DJ, et al. Tolerability, dose intensity and benefit of 5FU based chemotherapy for advanced colorectal cancer (CRC) in the elderly: a North Central Cancer Treatment Group Study [abstract]. Proc Am Soc Clin Oncol 2001; 20(384a): 1534

    Google Scholar 

  23. Stein BN, Petrelli NJ, Douglass HO, et al. Age and sex are independent predictors of 5-fluorouracil toxicity. Cancer 1995; 75: 11–7

    Article  PubMed  CAS  Google Scholar 

  24. Saltzman JR, Russe RM. The aging gut: nutritional issues. Gastroenterol Clin North Am 1998; 27: 305–24

    Article  Google Scholar 

  25. Kemeny N, Fata F. Arterial, portal or systemic chemotherapy for patients with hepatic metastases from colorectal carcinoma. J Hepatobiliary Pancreat Surg 1999; 6: 39–49

    Article  PubMed  CAS  Google Scholar 

  26. Budman GR, Meropol NJ, Reigner B. Preliminary studies of a novel oral fluoropyrimidine carbamate: capecitabine. J Clin Oncol 1998; 16: 1795–80

    PubMed  CAS  Google Scholar 

  27. Balducci L, Hardy CH, Lyman GH. Hemopoietic growth factors in the older cancer patient. Curr Opin Hematol 2001 May; 8(3): 170–87

    Article  PubMed  CAS  Google Scholar 

  28. Balducci L, Hardy CL, Lyman GH. Hemopoietic reserve in the older cancer patient: clinical and economic considerations. Cancer Control 2000; 7(6): 539–47

    PubMed  CAS  Google Scholar 

  29. Zinzani PG, Storti S, Zaccaria A, et al. Elderly aggressive histology non-Hodgkin’s lymphoma: first line VNCOP-B regimen: experience on 350 patients. Blood 1999; 94: 33–8

    PubMed  CAS  Google Scholar 

  30. Sonneveld P, de Ridder M, van der Lelie H, et al. Comparison of doxorubicin and mitoxantrone in the treatment of elderly patients with advanced diffuse non-Hodgkin’s lymphoma using CHOP vsCNOP chemotherapy. J Clin Oncol 1995; 13: 2530–9

    PubMed  CAS  Google Scholar 

  31. Gomez H, Mas L, Casanova L, et al. Elderly patients with aggressive non-Hodgkin’s lymphoma treated with CHOP chemotherapy plus granulocyte-macro-phage colony-stimulating factor: identification of two age subgroups with differing hematologie toxicity. J Clin Oncol 1998; 16: 2352–8

    PubMed  CAS  Google Scholar 

  32. Tirelli U, Errante D, Van Glabbeke M, et al. CHOP is the standard regimen in patients ≥70 years of age with intermediate and high grade non-Hodgkin’s lymphoma: results of a randomized study of the European organization for the Research and Treatment of Cancer Lymphoma Cooperative Study. J Clin Oncol 1998; 16: 27–34

    PubMed  CAS  Google Scholar 

  33. Bastion Y, Blay JY, Divine M, et al. Elderly patients with aggressive non-Hodgkin’s lymphoma: disease presentation, response to treatment and survival: a Groupe d’Etude des Lymphomes de l’Adulte Study on 453 patients older than 69 years. J Clin Oncol 1997; 15: 2945–53

    PubMed  CAS  Google Scholar 

  34. Bertini M, Freilone R, Vitolo U, et al. The treatment of elderly patients with aggressive non-Hodgkin’s lymphomas: feasibility and efficacy of an intensive multidrug regimen. Leuk Lymphoma 1996; 22: 483–93

    Article  PubMed  CAS  Google Scholar 

  35. O’Reilly SE, Connors JM, Howdle S, et al. In search of an optimal regimen for elderly patients with advanced-stage diffuse large-cell lymphoma: results of a phase II study of P/DOCE chemotherapy. J Clin Oncol 1993; 11: 2250–7

    PubMed  Google Scholar 

  36. Armitage JO, Potter JF. Aggressive chemotherapy for diffuse histiocytic lymphoma in the elderly. J Am Geriatr Soc 1984; 32: 269–73

    PubMed  CAS  Google Scholar 

  37. Bjorkholm M, Osby E, Hagberg H, et al. Randomized trial of R-methu granulocyte colony stimulating factors as adjunto to CHOP or CNOP treatment of elderly patients with aggressive non-Hodgkin’s lymphoma [abstract no. 2665]. Blood 1999; 94: 599a

    Google Scholar 

  38. Zagonel V, Babare R, Merola MC, et al. Cost-benefit of granulocyte colony-stimulating factor administration in older patients with non-Hodgkin’s lymphoma treated with combination chemotherapy. Ann Oncol 1994; 5 Suppl. 2: 127–32

    Article  Google Scholar 

  39. Extermann M, Aapro M. Assessment of the older cancer patient. Hematol Oncol Clin North Am 2000; 14(1): 63–78

    Article  PubMed  CAS  Google Scholar 

  40. Extermann M. Assessing the older cancer patient. Oncol Spectrums. In press

  41. Extermann M, Balducci L, Lyman GH. What threshold for adjuvant therapy in older breast cancer patients? J Clin Oncol 2000; 18: 1709–17

    PubMed  CAS  Google Scholar 

  42. Reuben DB, Rubenstein LV, Hirsch SH, et al. Value of functional status as predictor of mortality. Am J Med 1992; 93: 663–9

    Article  PubMed  CAS  Google Scholar 

  43. Piccirillo JF, Feinstein AR. Clinical symptoms and comorbidity: significance for the prognostic classification of cancer. Cancer 1996; 77: 834–42

    Article  PubMed  CAS  Google Scholar 

  44. Bruce ML, Hoff RA, Jacobs SC, et al. The effect of cognitive impairment on 9-year mortality in a community sample. J Gerontol B Psychol sci Soc sci 1995; 50: 289–96

    Article  Google Scholar 

  45. Covinsky KE, Kahana E, Chin MH, et al. Depressive symptoms and three year mortality in older hospitalized medical patients. Ann Intern Med 1999; 130: 563–9

    PubMed  CAS  Google Scholar 

  46. Tinetti ME, Williams CS. The effects of falls and fall injuries in functioning in community dwelling older persons. J Gerontol 1998; 53A: Ml 12–9

    Google Scholar 

  47. Rockwood K, Stadnyk K, Macknigt C, et al. A brief instrument to classify frailty in elderly people. Lancet 1999; 353: 205–6

    Article  PubMed  CAS  Google Scholar 

  48. Verdery RB. Failure to thrive in old age: follow-up on a workshop. J Gerontol A Biol sci Med sci 1997; 52: M333–6

    Article  PubMed  CAS  Google Scholar 

  49. Dyer CB, Pavlick VN, Murphy KP, et al. The high prevalence of depression and dementia in elder abuse or neglect. J Am Geriatr Soc 2000; 48: 205–8

    PubMed  CAS  Google Scholar 

  50. Haley WE, Ehrbar L, Schonwetter RS. Family caregiving issues. In: Balducci L, Lyman GH, Ershler WB, editors. Comprehensive geriatric oncology. London: Harwood Academic Publishers, 1998: 805–12

    Google Scholar 

  51. Extermann M, Overcash J, Lyman GH, et al. Comorbidity and functional status are independent in older cancer patients. J Clin Oncol 1998; 16: 1582–7

    PubMed  CAS  Google Scholar 

  52. Hamermann D. Toward an understanding of frailty. Ann Intern Med 1999; 130: 945–50

    Google Scholar 

  53. Balducci L, Stanta G. Cancer in the frail patient: a coming epidemic. Hematol Oncol Clin North Am 2000; 14: 235–50

    Article  PubMed  CAS  Google Scholar 

  54. Balducci L, Extermann M. Management of the frail cancer patient. Crit Rev Oncol Hematol 2000; 33: 143–8

    Article  PubMed  CAS  Google Scholar 

  55. Fried LP, Tangen CM, Walston J, et al. Frailty in older adults: evidence for a phenotype. J Gerontol A Biol sci Med sci 2001; 56: M146–56

    Article  PubMed  CAS  Google Scholar 

  56. Pieper CF, Murali K, Rao K, et al. Age, functional status and racial differences in plasma D-Dimer levels in community-dwelling elderly persons. J Gerontol A Biol sci Med sci 1997; 55: M649–57

    Article  Google Scholar 

  57. Sheehan DC, Forman WB. Symptomatic management of the older person with cancer. Clin Geriatr Med 1997; 13: 203–20

    PubMed  CAS  Google Scholar 

  58. Sun W, Haller D. UFT in the treatment of colorectal and breast cancer. Oncology (Huntingt) 2001; 15 Suppl. 1: 49–56

    Google Scholar 

  59. Diasio RB. Improving 5-FU with a novel dihydropyrimidine dehydrogenase inactivator. Oncology 1998; 12 Suppl. 4: 51–6

    Google Scholar 

  60. Blum JL, Buzdar A, Dieras V, et al. A multicenter phase II trial of capecitabine in paclitaxel refractory-metastatic breast cancer. J Clin Oncol 1999; 17(2): 485–93

    PubMed  CAS  Google Scholar 

  61. O’Reilly S, Moiseyenko V, Bell D, et al. A randomized phase two study of Xeloda (capecitabine) vs paclitaxel in breast cancer patients failing previous anthracycline therapy [abstract]. Proc Am Soc Clin Oncol 1998; 17: 627a

    Google Scholar 

  62. O’Shaughnessy J, Moiseyenko V, Bell D, et al. A randomized phase II study of Xeloda (capecitabine) vs CMF as front-line chemotherapy of breast cancer in women aged greater than 55 years [abstract]. Proc Am Soc Clin Oncol 1998; 17: 398a

    Google Scholar 

  63. Twelves C, Harper P, Van Cutsem E, et al. A phase three trial in previously untreated advanced /metastatic colorectal cancer [abstract]. Proc Am Soc Clin Oncol 1999; 18: 263a

    Google Scholar 

  64. Lozano RD, Patt YZ, Hassan MM, et al. Oral capecitabine for the treatment of hepatobiliary cancers [abstract]. Proc Am Soc Clin Oncol 2000; 19: 264a

    Google Scholar 

  65. Felius S, Gonzalez-Baron M, Espinosa E, et al. Uracil and tegafur modulated with LV: an effective regimen with low toxicity for the treatment of colorectal carcinoma in the elderly. Cancer 1997; 79: 1884–9

    Article  Google Scholar 

  66. Pazdur R, Donillard JY, Skillings JR, et al. Multicenter phase III study of 5 fluorouracil or UFTTM in combination with leucovorin in patients with metastatic colorectal cancer [abstract]. Proc Am Soc Clin Oncol 1999; 18: 1009a

    Google Scholar 

  67. Carmichael J, Popiela T, Raditon D, et al. Randomized comparative study of orzel (UFT plus leucovorin) vs parenteral 5-Fluorouracil plus leucovorin in patients with metastatic colorectal cancer [abstract]. Proc Am Soc Clin Oncol 1999; 18: 1015a

    Google Scholar 

  68. Ota K, Tagnchi T, Kimara K, et al. Report on national pooled data and cohort investigation of UFT in phase II study. Cancer Chemother Pharmacol 1988; 22: 333–8

    Article  PubMed  CAS  Google Scholar 

  69. RicharetE, Mickienwiez E, Lerzo G, et al. UFT plus leucovorin in advanced breast cancer: preliminary results in heavily pretreated patients [abstract]. Proc Am Soc Clin Oncol 1999; 19: 869a

    Google Scholar 

  70. Rivera E, Chevlen E, Eckardt J, et al. A phase II open label study to evaluate a 28-day oral regimen of 5-fluorouracil plus 776C85 for the treatment of patients with taxane and anthracycline resistant advanced breast cancer [abstract]. Proc Am Soc Clin Oncol 1998; 17: 113a

    Google Scholar 

  71. Burris HA, Ravdin P, Gutheil J, et al. Eniluracil/5FU in anthracycline and taxane refractory breast cancer [abstract]. Proc Am Soc Clin Oncol 1999; 18: 17a

    Google Scholar 

  72. Goldberg RM, Kugler J, Mahoney MR, et al. A phase II trial of 7 days of orla 776C85 plus 5 days of 5-Fluorouracil in patients with metastatic colorectal cancer: a North Central Cancer Treatment Group Study [abstract]. Proc Am Soc Clin Oncol 2000; 19: 245a

    Google Scholar 

  73. Mani S, Beck T, Chevlen E, et al. A phase II open label study to evaluate a 28 day regimen of oral 5-fluorouracil plus 776C85 for the treatment of patients with previously untreated metastatic colorectal cancer [abstract]. Proc Am Soc Clin Oncol 1998; 17: 281a

    Google Scholar 

  74. Vanhofer U, Wilke H. Oral fluoropyrimidine based combination therapy in gastrointestinal cancer. Oncology (Huntingt) 2001; 15 Suppl. 1: 79–84

    Google Scholar 

  75. Esteva FJ, Valero V, Pusztai L, et al. Chemotherapy of metastatic breast cancer: what to expect in 2001 and beyond. Oncologist 2001; 6: 133–46

    Article  PubMed  CAS  Google Scholar 

  76. Phillis NC. Oral etoposide. Drug Intell Clin Pharm 1988; 22: 860–3

    Google Scholar 

  77. Ando M, Minami H, Uger DR, et al. Pharmacological analysis of etoposide in elderly patients with lung cancer. Clin Cancer Res 1999; 5: 1690–5

    PubMed  CAS  Google Scholar 

  78. Souhami RL, Spiro SG, Rudd RM, et al. Five days oral etoposide treatment for advanced Small Cell Lung Cancer (SCLC): randomized comparison with intravenous chemotherapy. J Natl Cancer Inst 1997; 89: 1892–3

    Article  Google Scholar 

  79. Ozols RF. Oral etoposide for the treatment of recurrent ovarian cancer. Drugs 1999; 58 Suppl. 3: 43–9

    Article  Google Scholar 

  80. Kamradt JM, Pienta KJ. Etoposide in prostate cancer. Expert Opin Pharmacother 2000; 1: 271–5

    Article  PubMed  CAS  Google Scholar 

  81. Okamoto T, Nishimura Y, Yamada S, et al. Long-term administration of oral low-dose topoisomerase II in MST-16 and VP-16 for refractory or relapsed non-Hodgkin’s lymphoma. Ada Haematol 2000; 104: 128–30

    Article  CAS  Google Scholar 

  82. Greco FA. Oral etoposide in lymphoma. Drugs 1999; 58 Suppl. 3: 35–41

    Article  Google Scholar 

  83. Remick SC, Sedransk N, Haase RF, et al. Oral combination chemotherapy in conjunction with filgrastim (G-CSF) in treatment of AIDS-related non-Hodgkin’s lymphoma: evaluation of the role of G-CSF; quality of life analysis and long term follow-up. Am J Hematol 2001; 66: 178–88

    Article  PubMed  CAS  Google Scholar 

  84. Beale P, Judson I, Moore S, et al. Effect of gastric pH on the relative oral bioavailability and pharmacokinetics of temozolomide. Cancer Chemother Pharmacol 1999; 44: 389–94

    Article  PubMed  CAS  Google Scholar 

  85. Middleton MR, Grob JJ, Aaronson N, et al. Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced malignant melanoma. J Clin Oncol 2000; 18: 158–66

    PubMed  CAS  Google Scholar 

  86. Christodoulou C, Bafaloukos D, Kosmidis P, et al. Phase II study of temozolomide in heavily pretreated cancer patients with brain metastases. Ann Oncol 2001; 12: 249–54

    Article  PubMed  CAS  Google Scholar 

  87. Newland ES, Blackledge GRP, Slack JA, et al. Phase I trial of temozolomide (CCRG 81045: M & B 39832: NSC 362856). Br J Cancer 1992; 65: 287–91

    Article  Google Scholar 

  88. Bengston EM, Rigas JR. New oral chemotherapeutic agents for lung cancer. Drugs 1999; 58 Suppl. 3: 57–69

    Google Scholar 

  89. Winer ER, Chu L, Spicer DV, et al. Oral vinorelbine in the treatment of advanced breast cancer. Semin Oncol 1995; 22 Suppl. 5: 72–8

    Google Scholar 

  90. Vokes EE, Rosenberg RK, Jahanzeb M, et al. Multicenter phase II study of weekly oral vinorelbine for stage 4 non-small cell lung cancer. J Clin Oncol 1995; 13: 637–44

    PubMed  CAS  Google Scholar 

  91. Kalland JR. An update of satraplatin, the first oral available platinum anticancer drug. Exp Opin Investig Drugs 2000; 9: 1373–82

    Article  Google Scholar 

  92. Malongre MM, Beijnen JH, Schellens JH. Oral delivery of taxanes. Invest New Drugs 2001; 19: 155–62

    Article  Google Scholar 

  93. Gelderblom HA, De Jong MG, Spaneboom A, et al. Oral topoisomerase 1 inhibitors in adults: present and future. Invest New Drugs 1999; 17: 401–15

    Article  PubMed  CAS  Google Scholar 

  94. Drucker BJ, Talpaz M, Resta DJ, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001; 344: 1031–7

    Article  Google Scholar 

  95. Joensuu H, Roberts PJ, Sarlomo-Rikala M, et al. Effect of the thyrosine kinase inhibitor STI571 in a patient with metastatic gastrointestinal stromal tumor. N Engl J Med 2001; 344: 1052–6

    Article  PubMed  CAS  Google Scholar 

  96. Swaisland H, Laight A, Stafford L, et al. Pharmacokinetics and tolerability of the orally active selective epidermal growth factor receptor tyrosine kinase inhibitor in healthy volunteers. Clin Pharmacokinet 2001; 40: 297–306

    Article  PubMed  CAS  Google Scholar 

  97. Adjei AA. Blocking oncogenic Ras signaling for cancer therapy. J Natl Cancer Inst 2001; 93: 1062–74

    Article  PubMed  CAS  Google Scholar 

  98. Weng DE, Usman N. Angiozyme: a novel angiogenesis inhibitor. Curr Oncol Rep 2001; 3: 141–6

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Oncology, University of Palermo School of Medicine, Palermo, Italy

    Ignazio Carreca

  2. Senior Adult Oncology Program, University of South Florida College of Medicine, H. Lee Moffitt Cancer Center & Research Institute, 12902 Magnolia Drive, Tampa, FL, 33612, USA

    Lodovico Balducci

Authors
  1. Ignazio Carreca
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Lodovico Balducci
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Lodovico Balducci.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Carreca, I., Balducci, L. Oral Chemotherapy for the Older Patient with Cancer. Am J Cancer 1, 101–108 (2002). https://doi.org/10.2165/00024669-200201020-00003

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00024669-200201020-00003

Keywords

Search

Navigation